Naturally Splendid Appoints David Racz as Director and President of Naturally Splendid USA

Life Science Investing News

Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) announced that David Racz has been appointed as Director and President of Naturally Splendid USA Ltd. Mr. Racz has held global, senior-level positions with pharmaceutical companies including Pfizer, GlaxoSmithKline and Novartis.

Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) announced that David Racz has been appointed as Director and President of Naturally Splendid USA Ltd. Mr. Racz has held global, senior-level positions with pharmaceutical companies including Pfizer, GlaxoSmithKline and Novartis.

As quoted in the press release:

Naturally Splendid Enterprises (the “Company”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to announce the appointment of Mr. David Racz to the Board of Directors of the Company and as President of the Company’s 100% owned subsidiary Naturally Splendid USA Ltd., based in Denver, Colorado. Mr. Racz will replace Mr. Charles Brink as President of the US subsidiary in order for Mr. Brink to focus his attention on his role and responsibilities as a Director of the parent Company Naturally Splendid Enterprises where his duties include; regulatory guidance; product development; and long term business strategies.

Naturally Splendid CEO Craig Goodwin advises, “Mr. Racz is a senior operations and general management executive with a distinguished career and demonstrated successes in both large matrix organizations as well as startups. He has extensive international operations experience and has worked in the pharmaceutical, consumer brands and retail industries. His expertise and guidance will be invaluable as we execute strategies to monetize the omega extraction and formulation technologies and cannabinoid extraction and formulation technologies recently licensed from Full Spectrum Laboratories”.
David Racz

Mr. Racz held global, senior-level positions with distinguished pharmaceutical companies including Pfizer, GlaxoSmithKline and Novartis. Mr. Racz began his pharmaceutical career in the late 1980s at Pfizer Pharmaceuticals where he became Vice President of Sales and Human Resources. In addition to being tasked with overseeing all strategy, recruitment and management training, Mr. Racz managed the largest expansion in Pfizer’s sale force history. Shortly thereafter, SmithKlineBeecham recruited Mr. Racz to manage over 4,000 employees in 20 countries throughout Asia, Latin America, Australia and South Africa in Sales, Marketing and Research and Development. Mr. Racz was also a key member of the team responsible for orchestrating the unparalleled transcontinental merger of SmithKline and Beecham. In 2002, Mr. Racz was recruited by Novartis Pharmaceuticals as Senior Vice President HR. In this capacity he delivered HR strategy and resource allocation for an $8 billion health care company and oversaw 14,000 global employees in Pharmaceutical Operations, Global Oncology, Manufacturing and R&D. Mr. Racz was Senior Vice President for Mona Vie Inc. (“Mona Vie”), the fastest growing private company in the food and beverage industry incorporated in 2003 with annual sales in excess of $942 million and growth of over 100% per quarter for a three year period.
In addition, Mr. Racz has been responsible for leading human resource teams, sales and marketing teams and operating entities. He has served on various boards of both private and public companies. His primary areas of expertise reside in aligning business strategy with operational strategy, management systems, as well as merger and acquisition related activities. Mr. Racz has several years of experience in the network marketing industry working on the corporate level as well as with some of the most successful distributors to participate in the industry. Mr. Racz has served on various boards of both private and public companies. He served in the United States Army as a helicopter pilot, achieving the rank of Major and earned his BS from Wayne State University and his MS from Troy State University
Mr. Racz’s appointment as President of Naturally Splendid USA comes following the recently completed agreement with Full Spectrum Laboratories Limited (FSL) headquartered in Dublin, Ireland, to license FSL’s cannabinoid extraction and patented formulation technologies. The license grants Naturally Splendid USA worldwide rights to a suite of advanced cannabinoid technologies, including the first issued USPTO patent for water-soluble cannabinoids, essential for the development and manufacturing of cannabinoid-based nutraceutical and pharmaceutical products and therapies. The license will allow Naturally Splendid USA to create products and industrial solutions in those countries and jurisdictions that permit manufacturing and distribution of cannabinoid-based products.

Click here to read the Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) press release
Click here to see the Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) profile.

The Conversation (0)
×